Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344pembrolizumab 331Gemcitabine 331Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 287Bevacizumab 250Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 190fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 152Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 128Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × MM-111 × Clear all
NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Merrimack Pharmaceuticals

Phase 2 Terminated
84 enrolled 10 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡